SWOT Analysis for Adma Biologics Inc

Consistent Highest Return Stocks over Five Years
Significant (over 30%) distance from 52 week high
Mid-range Performer (DVM)
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over 1 Year
Big Gainers in Share Price with Good Net Profit Growth
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 10 Years
Good quarterly growth in the recent results
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Companies with Low Debt
Companies with reducing Debt
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Volume Shockers

Promoter decreasing their shareholding
Negative Breakdown First Support (LTP < S1)
Stocks with Quarter Change % less than Industry
PE higher than Industry PE
Top Losers
Negative Breakdown First Support (LTP < S1)
Weak Momentum: Price below Short, Medium and Long Term Averages
Declining Revenue every quarter for the past 2 quarters
RSI indicating price weakness
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter